7 Patients Randomized. $1,714 Per Randomized Patient.

For biotech sponsors running their own study sites or working with early-phase CROs, enrollment timelines are tied directly to capital runway. A study running 90 days behind enrollment projections is not just a clinical problem. It is a financing problem. Investors track milestones. Delayed data readouts push reporting windows. The cost of slow enrollment in a capital-constrained biotech environment is measured in more than coordinator hours.

Blue Lake Biotechnology's Pediatric Vaccine study needed patients enrolled within a defined window. The internal resources available for patient outreach were limited by the organization's operational scale. Developing IRB-ready campaign materials, establishing media placements, and managing pre-screening logistics required infrastructure the organization did not have in-house.

The alternative: engaging a traditional recruitment vendor with fees payable regardless of randomization outcomes. For a biotech operating with budget discipline, that structure was not acceptable.

The campaign delivered 7 randomized patients against a $12,000 investment, a cost per randomized patient of $1,714.

Per-patient site fees for pediatric vaccine studies vary by protocol structure and phase. At an estimated $3,000 to $10,000 per-patient site fee, 7 randomized patients represents a potential $21,000 to $70,000 in patient revenue against a $12,000 campaign investment.

The contractual randomization structure meant Blue Lake Biotechnology's recruitment budget was tied to a defined outcome, not an activity report. For a capital-disciplined organization, that distinction carries material weight at the budget approval level.